SCHEMBL546219

SCHEMBL546219

CCCCCCCCCS([O])(=O)=O

nearest known ligand 0.59

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.59
CA2 P00918 6/20 0.52
TSHR P16473 1/20 0.47
THRB P10828 1/20 0.47
CES1 P23141 5/20 0.42
CES2 O00748 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL547132 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL77261 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL304723 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL296297 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL4880167 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL303807 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL77270 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL4880544 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL301132 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1
SCHEMBL303667 1.00 FAAH (0.59) FAAHCA2TSHRTHRBCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023162551-A1 METHOD FOR PRODUCING PLATED SHAPED ARTICLE 東京応化工業株式会社 2023-08-31 WO disclosed
WO-2023162552-A1 CHEMICALLY AMPLIFIED POSITIVE PHOTOSENSITIVE COMPOSITION, PRODUCTION METHOD FOR SUBSTRATE WITH TEMPLATE, AND PRODUCTION METHOD FOR PLATED ARTICLE 東京応化工業株式会社 2023-08-31 WO disclosed
CN-105980300-B Fullerene derivative, organic solar cell using same, and method for manufacturing same 株式会社LG化学 2017-09-15 CN disclosed
CN-105980300-A Fullerene derivative, organic solar cell using same, and method for manufacturing same 株式会社LG化学 2016-09-28 CN disclosed
US-9255070-B2 Method of deuteration using mixed catalyst WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2016-02-09 US disclosed
US-8524440-B2 Photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-09-03 US disclosed
US-8110336-B2 Resin and chemically amplified resist composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-02-07 US disclosed
US-8071270-B2 Polyhydric compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-06 US disclosed
US-20110165513-A1 PHOTORESIST COMPOSITION SUMITOMO CHEMICAL COMPANY LTD (JP) 2011-07-07 US disclosed
CN-102117013-A Photoresist composition SUMITOMO CHEMICAL CO 2011-07-06 CN disclosed
US-20100075257-A1 Resin and Chemically Amplified Resist Composition Comprising the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-25 US disclosed
US-20090220886-A1 POLYHYDRIC COMPOUND AND CHEMICALLY AMPLIFIED RESIST COMPOSITION CONTAINING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-09-03 US disclosed
CN-101514173-A Polyhydric compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL CO (JP) 2009-08-26 CN disclosed
US-20080234488-A1 Method of Deuteration Using Mixed Catalyst WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-09-25 US disclosed
CN-1906143-A Method of deuteration using mixed catalyst WAKO PURE CHEM IND LTD (JP) 2007-01-31 CN disclosed
EP-1707548-A1 METHOD OF DEUTERATION USING MIXED CATALYST Wako Pure Chemical Industries, Ltd. (JP) 2006-10-04 EP disclosed
US-5691319-A ANTICARCINOGENIC AGENTS SANKYO COMPANY, LIMITED (JP) 1997-11-25 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
US-4124579-A FOR POLYMERIC MATERIALS IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) 1978-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234488-A1 Method of Deuteration Using Mixed Catalyst HDHD5, DHX35, HRH3 FAAH 1707/4885CA2 1953/4885TSHR 2222/4885
US-20090220886-A1 POLYHYDRIC COMPOUND AND CHEMICALLY AMPLIFIED RESIST COMPOSITION CONTAINING THE SAME C5, C1R, H1-4 FAAH 2525/4885CA2 310/4885TSHR 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.